Valneva has bolstered its vaccines pipeline with a shot designed to protect against shigellosis – a major global health threat – licensed from LimmaTech Biologics.
Agomab Therapeutics has closed a $100 million third-round financing, heading a list of recent funding rounds that also features AstronauTx, MinervaX, Precede Bio and Limma
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl